Literature DB >> 16450135

Short fluorodeoxyuridine exposure of different human glioblastoma lines induces high-level accumulation of S-phase cells that avidly incorporate 125I-iododeoxyuridine.

Florence Perillo-Adamer1, Angelika Bischof Delaloye, Céline S Genton, Andreas O Schaffland, Yves M Dupertuis, Franz Buchegger.   

Abstract

PURPOSE: Radio-iododeoxyuridine (IdUrd) is a potential Auger radiation therapy agent incorporated into DNA during the synthesis phase. In this study we sought to optimise S-phase targeting by modulating cellular cycling and radio-IdUrd DNA incorporation using short non-toxic fluorodeoxyuridine (FdUrd) incubations.
METHODS: Three human glioblastoma cell lines with different p53 expression were pre-treated with various FdUrd conditions. After different intervals, (125)I-IdUrd DNA incorporation was measured. Fluorescence-activated cell sorter cell cycle analysis was performed after identical intervals post FdUrd pre-treatment.
RESULTS: The highest increase in (125)I-IdUrd DNA incorporation was induced by 1-h incubation with 1 muM FdUrd. Increase in radio-IdUrd DNA incorporation was greatest 16-24 h after FdUrd, reaching factors of >or=7.5 over baseline incorporation in the three cell lines. Furthermore, cell synchronisation in S phase was observed with a peak of >or=69.5% in the three cell lines at 16 and 24 h post FdUrd, corresponding to an increase of 2.5-4.1 over baseline.
CONCLUSION: FdUrd-induced thymidine synthesis inhibition led to S-phase accumulation that was maximal after an interval of 16-24 h and time-correlated with the highest radio-IdUrd DNA incorporation. These observations might allow the rational design of an Auger radiation therapy targeting a maximal number of S-phase cells in single treatment cycles.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16450135     DOI: 10.1007/s00259-005-0009-y

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  24 in total

1.  Fluorodeoxyuridine improves imaging of human glioblastoma xenografts with radiolabeled iododeoxyuridine.

Authors:  Y M Dupertuis; M Vazquez; J P Mach; N De Tribolet; C Pichard; D O Slosman; F Buchegger
Journal:  Cancer Res       Date:  2001-11-01       Impact factor: 12.701

2.  Variations in several responses of HeLa cells to x-irradiation during the division cycle.

Authors:  T TERASIMA; L J TOLMACH
Journal:  Biophys J       Date:  1963-01       Impact factor: 4.033

3.  Biological stability of 5-iodo-2'-deoxyuridine labelled with iodine-125 after its incorporation into the deoxyribonucleic acid of the mouse.

Authors:  S L Commerford
Journal:  Nature       Date:  1965-05-29       Impact factor: 49.962

4.  Novel deoxynucleoside-phosphorylating enzymes in mycoplasmas: evidence for efficient utilization of deoxynucleosides.

Authors:  L Wang; J Westberg; G Bölske; S Eriksson
Journal:  Mol Microbiol       Date:  2001-11       Impact factor: 3.501

5.  Modulation of [5-125I]iododeoxyuridine incorporation into tumour and normal tissue DNA by methotrexate and thymidylate synthase inhibitors.

Authors:  J Mester; K DeGoeij; M Sluyser
Journal:  Eur J Cancer       Date:  1996-08       Impact factor: 9.162

6.  Radiotoxicity of 5-[125I]iodo-2'-deoxyuridine in mammalian cells following treatment with 5-fluoro-2'-deoxyuridine.

Authors:  A I Kassis; W E Guptill; R A Taube; S J Adelstein
Journal:  J Nucl Biol Med       Date:  1991 Jul-Sep

7.  The preparation of clinical grade 5-[123I]iodo-2'-deoxyuridine and 5-[125I]iodo-2'-deoxyuridine with high in vitro stability and the potential for early proliferation scintigraphy.

Authors:  Andreas O Schaffland; Angelika Bischof Delaloye; Marek Kosinski; Yves M Dupertuis; Franz Buchegger
Journal:  Nucl Med Commun       Date:  2004-05       Impact factor: 1.690

8.  Timing and role of p53 gene mutation in the recurrence of glioma.

Authors:  Y Hayashi; J Yamashita; K Yamaguchi
Journal:  Biochem Biophys Res Commun       Date:  1991-10-31       Impact factor: 3.575

9.  Clinical pharmacology of 5-iodo-2'-deoxyuridine and 5-iodouracil and endogenous pyrimidine modulation.

Authors:  R W Klecker; J F Jenkins; T J Kinsella; R L Fine; J M Strong; J M Collins
Journal:  Clin Pharmacol Ther       Date:  1985-07       Impact factor: 6.875

10.  Inhibition of [3H]thymidine incorporation by Mycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside.

Authors:  F Sinigaglia; K W Talmadge
Journal:  Eur J Immunol       Date:  1985-07       Impact factor: 5.532

View more
  3 in total

Review 1.  Auger radiation targeted into DNA: a therapy perspective.

Authors:  Franz Buchegger; Florence Perillo-Adamer; Yves M Dupertuis; Angelika Bischof Delaloye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-08-08       Impact factor: 9.236

2.  Azidothymidine enhances fluorodeoxyuridine-mediated radiosensitization.

Authors:  Chang-Ming Chen; Monika Johnson; Brian J Smith; Ken Dornfeld
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

Review 3.  Auger processes in the 21st century.

Authors:  Roger W Howell
Journal:  Int J Radiat Biol       Date:  2008-12       Impact factor: 2.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.